4.7 Article

HA-DOPE-Modified Honokiol-Loaded Liposomes Targeted Therapy for Osteosarcoma

期刊

INTERNATIONAL JOURNAL OF NANOMEDICINE
卷 17, 期 -, 页码 5137-5151

出版社

DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJN.S371934

关键词

honokiol; liposomes; osteosarcoma; hyaluronic acid

资金

  1. Xinglin young scholar construction of high levels university projects of Guangzhou University of Chinese Medicine [A1-2601-21-414-001Z22, A1-AFD018201Z0352, A1-AFD018191Z0161]

向作者/读者索取更多资源

The study developed a nano drug delivery system by combining HNK-loaded liposomes with HA-DOPE modification, which demonstrated effective antitumor abilities in both in vitro and in vivo studies.
Purpose: Osteosarcoma (OS) is the most common bone cancer with a high risk of metastasis, high growth rate, and poor prognosis. Honokiol (HNK) is a general ingredient of traditional Chinese medicine, with a potential anti-tumor effect. However, HNK is insoluble in water and lacks drug targeting, which limits its clinical application. To improve the OS therapeutic effect of HNK, we used HNK-loaded liposomes modified with hyaluronic acid-phospholipid conjugates (HA-DOPE) to treat OS based on the HA interaction with CD44.Methods: The HNK-loaded liposomes were prepared via thin-film hydration and sonication. HA-DOPE was used to combine the HNK-loaded liposomes (HA-DOPE@Lips/HNK) via sonication and co-extrusion. HA-DOPE@Lips/HNK were characterized with respect to size, zeta potential, polymer dispersity index (PDI), and stability, and transmission electron microscopy was performed. Cellular uptake, cell viability, cell apoptosis, cell cycle, and mitochondrial activity were utilized to evaluate the antitumor effect in vitro. The biodistribution, xenograft tumor growth inhibition, and safety of HA-DOPE@Lips/HNK were evaluated in 143B OS xenograft mice in vivo.Results: The particle size, PDI, and zeta potential of HA-DOPE@Lips/HNK were 146.20 +/- 0.26 nm, 0.20 +/- 0.01, and -38.45 +/- 0.98 mV, respectively. The encapsulation rate and drug loading were 80.14 +/- 0.32% and 3.78 +/- 0.09%, respectively. HA-DOPE@Lips/HNK could inhibit cell proliferation, cause apoptosis, block the cell cycle and disrupt mitochondrial activity. HA-DOPE@Lips/HNK specially delivered the drug into the tumor and inhibited tumor growth, and showed no obvious toxicity to normal tissues.Conclusion: HA-DOPE@Lips/HNK could deliver HNK into the tumor site and had a good antitumor ability in vitro and in vivo. In addition, HA-DOPE@Lips/HNK increased the antitumor effects of HNK. Thus, it provides a promising nanocarrier to improve drug delivery in OS therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据